Gulf War Illness Inflammation Reduction Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02506192

Acronym

GWIIRT

Enrollment

Registered

2015-07-23

Start date

2015-07-31

Completion date

2023-10-19

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammation, Chronic Pain, Cognitive Impairment, Fatigue

Keywords

Gulf War Illness, Chronic Inflammation, Modified-Release Prednisone, Health-Related Quality of Life

Brief summary

The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes measures include changes from baseline levels of GWI-associated biomarkers of inflammation in peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and HRQOL with respect to mental functioning.

Detailed description

During Desert Shield and Desert Storm (Aug 2, 1990 to July 31,1991) 696,841 United States Military personnel were deployed to the Kuwaiti Theater of Operations. Today approximately one-third of those veterans are suffering from GWI, an unexplained chronic multi-symptom illness. Evidence of chronic inflammation in veterans with GWI has emerged from previous observational studies. The goal of this trial is to determine if reducing the GWI-associated chronic inflammation is an effective treatment for GWI. This is a randomized, two group, placebo controlled, double blind clinical trial. The treatment group will receive a low dose (2x5mg) once a day of delayed-release prednisone (Rayos) for 8 weeks. The placebo group will receive matching placebo (2x5mg) once a day for 8 weeks. The primary outcome measure for this clinical trial is a change from baseline of HRQOL with respect to physical functioning and symptoms. The secondary outcome measures include changes from baseline of peripheral blood levels of GWI-associated biomarkers of inflammation, changes from baseline of GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and a change from baseline of HRQOL with respect to mental functioning.

Interventions

DRUGModified-Release Prednisone

Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks

DRUGPlacebo

Placebo oral tablets (2x5mg) daily for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

double-blind, placebo-controlled

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Scores moderate-severe on at least 3 out of 6 domains from the Kansas GWI Case Definition * Deployed, (and honorably discharged), from the Kuwaiti Theater of Operation (August 2, 1990-July 31, 1991)

Exclusion criteria

* Hospitalization anytime since 1990 for Alcohol or Drug Dependence, Depression, or PTSD * Known hypersensitivity to Prednisone * Liver, (active or recent Hepatitis B or C treatment with a completion date within the past 6 months, or alcohol liver disease), or Kidney Disease (Hep B and C ok if after 6 months of treatment) * Treated Diabetes * Females who are Pregnant or Nursing * Female who refuses to use an accepted method of birth control * Exclusionary Labs: C-Reactive Protein \>25, Creatinine Clearance \<30, EFGR ≥ 30, Hgb A1-C \>7, Glucose \>120, WBC \>12, RBC \>6.2, Hematocrit \>60, Hemoglobin \<11, Platelets \<100, Liver Function Tests (2 x the upper limit of AST and ALT, 2 x the upper limit of Total Bilirubin, and Alkaline Phosphatase) * Has Inflammatory Arthritis (RA, or Psoriatic Arthritis, Spondylitis, Polyarthritis) * Reactive Arthritis, or IBD associated Arthritis * Has any major inflammatory disease (acute Chronic Infections, Ulcerative Colitis, Crohn's Disease, Inflammatory lung diseases- COPD or Asthma requiring steroid treatment, Pericarditis, Vasculitis) * Has an chronic/active infection * Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable) * Active Gum Disease or Dental Infection * Has been diagnosed with Lupus, Stroke, or Multiple Sclerosis. or any other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition * Has a condition that may interfere with the ability to accurately report symptoms, (Severe Psychiatric Problems, Schizophrenia, Bipolar Disorder, Alcohol or Drug Dependence requiring hospitalization, or regular illegal drug use) * Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months * Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year. * Hospitalization within the past 3 months

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) Scores at 8 and 16 Weeks	0, 8, and 16 weeks	The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS). To calculate PCS, scales are standardized with a scoring algorithm or by the scoring software. Scores are standardized and range from 0 to 100, with a US population mean of 50 points and a SD of 10 points. The PCS and the MCS have been demonstrated to have excellent psychometric properties. SF-36V PCS is a measure of HRQOL with respect to physical functioning and symptoms. Higher scores indicate better health status,

Secondary

Measure	Time frame	Description
Change From Baseline of McGill Pain Questionnaire-short Form (MPQ) Scores at 8 and 16 Weeks	0, 8, and 16 weeks	MPQ asks questions about sensory pain, affective pain, pain now, and typical pain
Change From Baseline of Multidimensional Fatigue Inventory (MFI) Scores at 8 and 16 Weeks	0, 8, and 16 weeks	MFI asks questions about general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue.
Change From Baseline of Cognitive Failures Questionnaire (CFQ) Scores at 8 and 16 Weeks	0, 8, and 16 weeks	CFQ asks questions about cognitive symptoms such as attention, concentration, and memory
Change From Baseline of Veterans RAND 36-Item Health Survey Mental Component Summary Score (MCS) Scores at 8 and 16 Weeks	0, 8, and 16 weeks	SF-36V MCS is a measure of HRQOL with respect to mental functioning. The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS). To calculate MCS, scales are standardized with a scoring algorithm or by the scoring software. Scores are standardized and range from 0 to 100, with a US population mean of 50 points and a SD of 10 points. The PCS and the MCS have been demonstrated to have excellent psychometric properties. SF-36V MCS is a measure of HRQOL with respect to mental functioning and symptoms. Higher scores indicate better health status,
Change From Baseline of Gulf War Illness-associated Peripheral Blood Biomarkers	0, 8, and 16 weeks	Peripheral blood biomarker levels are quantified by multi-analyte profiling (MAP) and complete blood count (CBC) analyses

Countries

United States

Participant flow

Participants by arm

Arm	Count
Modified-Release Prednisone Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm Modified-Release Prednisone: Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks	42
Placebo Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm Placebo: Placebo oral tablets (2x5mg) daily for 8 weeks	41
Total	83

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	Modified-Release Prednisone	Placebo	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	42 Participants	41 Participants	83 Participants
Age, Continuous	49.7 years STANDARD_DEVIATION 4	52.2 years STANDARD_DEVIATION 6.4	51.0 years STANDARD_DEVIATION 5.5
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	1 Participants	2 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	41 Participants	40 Participants	81 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants	1 Participants	2 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	2 Participants	2 Participants	4 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	39 Participants	38 Participants	77 Participants
Region of Enrollment United States	42 participants	41 participants	83 participants
Sex: Female, Male Female	2 Participants	3 Participants	5 Participants
Sex: Female, Male Male	40 Participants	38 Participants	78 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 42	0 / 41
other Total, other adverse events	0 / 42	0 / 41
serious Total, serious adverse events	0 / 42	0 / 41

Outcome results

Primary

Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) Scores at 8 and 16 Weeks

The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS). To calculate PCS, scales are standardized with a scoring algorithm or by the scoring software. Scores are standardized and range from 0 to 100, with a US population mean of 50 points and a SD of 10 points. The PCS and the MCS have been demonstrated to have excellent psychometric properties. SF-36V PCS is a measure of HRQOL with respect to physical functioning and symptoms. Higher scores indicate better health status,